AKAhmad Keelani

Ahmad Keelani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmad Keelani has a total of 192 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pressure-Waveform Guidance for Pulmonary Vein Occlusion During Cryoballoon Ablation: Procedural Efficiency and Repeat-Procedure Findings from a Large Single-Center Cohort

    by Obaida Alothman, Ahmad Keelani, Georgi Borisov, Markus Frommhold, Hytham Abdelwahab, Gabriele D’Ambrosio, Karam Issa, Sultan Alshehri, Santi Raffa, J. Christoph Geller

    Background/Objectives: The cryoballoon (CB) has simplified pulmonary vein isolation (PVI) for treating atrial fibrillation (AF). Vein occlusion is usually assessed utilizing contrast media which entails possible risks and increases fluoroscopy exposure. Pressure-guided assessment of occlusion has emerged as a potential alternative. The objective of this study is to compare procedural characteristics and repeat-procedure findings of pressure-guided and contrast-guided assessment of vein occlusion. Methods: From July 2018 to December 2023, 1166 patients (485 [41%] female, mean age 65 ± 10 years) with AF (64% paroxysmal) undergoing CB-PVI were enrolled at a single-center, 368 (32%) underwent a contrast-guided and 798 (68%) a pressure-guided approach. Results: Procedure duration (90 ± 20 vs. 93 ± 23 min) and ablation time (1342 ± 361 vs. 1368 ± 406 s) were similar in pressure- and contrast- guided groups, and the acute success rate of PVI was high in both groups. The pressure-guided approach had shorter X-ray times (5.7 ± 3.4 vs. 9.5 ± 4.8 min, p < 0.0001) and lower X-ray doses (82 ± 78.9 vs. 586 ± 546 cGy/cm2, p < 0.0001). In 112 redo-procedures for arrhythmia recurrence after CB-PVI, durable isolation of all veins was observed more often after pressure-guided procedures (28/56 [50%] vs. 13/56 [23%]); per-vein durability was also higher (174/224 [78%] vs. 150/224 [67%], p = 0.015). Conclusions: Pressure-waveform guidance during CB-PVI is a feasible alternative to contrast-guided occlusion assessment and was associated with substantially lower intraprocedural fluoroscopy exposure. Repeat-procedure findings suggest a possible durability signal, but this observation should be considered exploratory and confirmed in prospective studies.

  • Open Access

    Sex-based differences in the management and outcomes of oesophageal fistula following atrial fibrillation ablation: a subanalysis of the worldwide POTTER-AF study

    by Sorin Stefan Popescu, Anna Traub, Vanessa Schmidt, Helmut Pürerfellner, Philipp Sommer, Christian Sohns, Christian Veltmann, Daniel Steven, K R Julian Chun, Philippe Maury, et al.

    Aims: Oesophageal fistula (OF) is a rare but life-threatening complication of atrial fibrillation (AF) ablation. Data on sex-related differences in its management and outcomes are limited. Methods and results: The PrOgnosis following oesophageal fisTula formaTion in patients undergoing cathetER ablation for AF study is a global, multicentre study evaluating the incidence, management, and outcome of OF following AF ablation. Among 553 729 patients treated across 214 centres in 35 countries between 1996 and 2022, 138 developed OF. Sex-specific data on management and outcome were available in 117 cases and are analysed herein. Females comprised 47% of the analysed cohort. Baseline characteristics, ablation modality, and use of oesophageal temperature monitoring were not different between sexes in patients developing OF. Fewer women received proton pump inhibitors post-procedure (64.8% vs. 84.7%; P = 0.017). Among patients with OF, less women developed atrio-OF (90.9% vs. 100%; P = 0.021). Oesophageal perforation and oesophageal–pericardial fistula occurred exclusively in females. The median duration until symptoms onset was 20 days for women and 16.5 days for men (P = 0.14). Echocardiography was more frequently used in women (36.4% vs. 15%; P = 0.01). Stroke was more common in women (32.7% vs. 14.8%; P = 0.040), however only before adjusting for potential cofounders. Other complications were comparable. Women underwent endoscopic therapy more often (35.8% vs. 17.7%; P = 0.034) and surgical treatment alone less frequently (28.3% vs. 51.6%; P = 0.014). Fatality rates were high and not different (63.6% in women vs. 67.2% in men; P = 0.70). Conclusion: While OF incidence for each sex could not be calculated, nearly half of all patients with OF were female. Women underwent more often endoscopic and less often surgical interventions; outcomes were comparable.

  • Open Access

    Focal monopolar pulsed field ablation for focal right atrial tachycardia: feasibility and safety from a single-centre experience

    by Ahmad Keelani, Obaida Alothman, Salome Tavkhelidze, Neha Krishnaswami, Georgi Borisov, Markus Frommhold, Hytham Abdelwahab, Santi Raffa, Dominik Linz, J Christoph Geller

  • Open Access

    Safety and Midterm Outcome of Focal Pulsed Field Ablation for Outflow Tract Premature Ventricular Contractions

    by Ahmad Keelani, Salome Tavkhelidze, Lucija Lisica, Martin H. Ruwald, Sevasti-Maria Chaldoupi, Obaida Alothman, Georgi Borisov, Markus Frommhold, Hytham Abdelwahab, Arne Johannesen, et al.


  • Predictors of Favorable Neurological Outcomes Following Atrioesophageal Fistula After Radiofrequency Catheter Ablation for Atrial Fibrillation: A Subanalysis of the POTTER-AF Study

    by Kohei Ukita, Sorin Stefan Popescu, Vanessa Schmidt, Helmut Pürerfellner, Philipp Sommer, Christian Sohns, Christian Veltmann, Daniel Steven, K.R. Julian Chun, Philippe Maury, et al.

  • Open Access

    Influence of proton pump inhibitors on the incidence and clinical course of oesophageal fistula following catheter ablation for atrial fibrillation: a subanalysis of the POTTER-AF study

    by Thomas Beiert, Vincent Knappe, Andreas Zietzer, Vanessa Schmidt, Helmut Pürerfellner, Philipp Sommer, Christian Sohns, Christian Veltmann, Daniel Steven, Kyoung-Ryul Julian Chun, et al.


  • Open Access

    Safety and efficacy of atrial fibrillation ablation in kidney transplant patients

    by Ahmad Keelani, Lorenzo Bartoli, Alessio Gasperetti, Sorin Popescu, Marco Schiavone, Anna Traub, Huong-Lan Phan, Marcel Feher, Thomas Fink, Vanessa Sciacca, et al.

    Introduction: Managing atrial fibrillation in kidney transplant patients poses a challenge for both nephrologists and cardiologists. Data regarding the safety and efficacy of catheter ablation in this patient’s cohort is scarce. Methods and results: In this two-center prospective study, we included all consecutive kidney transplant patients who underwent atrial fibrillation ablation between April 2017 and March 2022. A 1:3 propensity score matching created a control group of non-transplant AF patients undergoing ablation. We included 16 kidney transplant patients and 48 matched controls. Ablation was successful in all patients. The periprocedural complication rate (6.3% in the kidney transplant group vs. 6.3% in the control group, p value = 1) did not differ between the two groups. One transplant patient experienced graft dysfunction after a complication. At 18 months, AF recurrence-fee rates were 69% in the transplant group and 70.1% in controls (p = 0.95). By the last follow-up, all transplant patients had discontinued antiarrhythmic drugs, while 19.6% of the patients in the control group were treated with antiarrhythmic drugs (p = 0.09). Kidney function in the transplant group remained stable (eGFR 32 [23.8, 40.5] ml/min/1.73 m2 before vs. 34 [29.8, 38] ml/min/1.73 m2 at last follow up, p = 0.93). Conclusions: This study demonstrates that catheter ablation is a viable option for treating AF in kidney transplant patients, with comparable outcomes to non-transplanted individuals. Discontinuing antiarrhythmic drugs reduces drug interaction risks, but minimizing procedural complications remains critical to preserving graft function. Graphical


  • Feasibility and Clinical Efficacy of Focal Pulsed Field Ablation in Patients With Non‐Pulmonary Vein Triggered Atrial Arrhythmia From the Superior Caval Vein

    by Ahmad Keelani, Obaida Alothman, Georgi Borisov, Markus Frommhold, Lorenzo Bartoli, Hytham Abdelwahab, Gabriele D'AMbrosio, Sultan Al Shehri, Santi Raffa, J. Christoph Geller

    Introduction: In patients with atrial arrhythmias originating from the superior vena cava (SVC), the use of radiofrequency energy to isolate the SVC is associated with a significant risk of injury both to the phrenic nerve and the sinus node. Pulsed field ablation (PFA) may overcome the disadvantages of thermal energy and improve both ablation efficacy and safety.Objective: We report the feasibility, safety, and clinical efficacy of focal monopolar PFA in patients with the origin of their atrial arrhythmia in the SVC.Methods: Nine patients (7 men, age 66 ± 8 years) with SVC‐induced paroxysmal AF (n = 3), persistent AF (n = 5), or frequent premature atrial beats (n = 1) underwent SVC isolation using focal monopolar PFA.Results: Acute circumferential SVC isolation was achieved in all cases, using 22 Ampere (A) or 25 A in areas with or without phrenic capture, respectively. The safety profile was excellent: two patients had transient sinus arrest and two had transient phrenic nerve stunning. Sinus node and phrenic nerve function recovered during the procedure, and no permanent damage was observed at follow‐up. Coronary vasospasm occurred (and quickly resolved after injection of nitroglycerin) in one patient during additional ablation of a focal atrial tachycardia at the coronary sinus ostium. Kidney function remained stable before and after ablation in all patients.Conclusions: In this patient cohort with SVC‐triggered atrial arrhythmia, isolation using focal monopolar PFA was feasible, effective, and safe. No permanent injury to the phrenic nerve or sinus node was observed.


  • Focal Pulsed Field Ablation for Premature Ventricular Contractions: A Multicenter Experience

    by Domenico Giovanni Della Rocca, María Cespón-Fernández, Ahmad Keelani, Santi Raffa, Luigi Pannone, Alexandre Almorad, Erwin Ströker, Georgi Borisov, Gezim Bala, Juan Sieira, et al.

    BACKGROUND: Pulsed field ablation (PFA) is a novel technology for catheter-based atrial arrhythmia treatment. Evidence of its application for ventricular arrhythmia ablation is still limited. In this study, we describe the feasibility and efficacy of focal PFA for premature ventricular contraction (PVC) ablation. METHODS: A prospective cohort of 20 patients referred for PVC ablation at 2 centers was enrolled, regardless of the presence of structural heart disease, PVC morphology, or previous ablation attempts. All procedures were performed using the CENTAURI System in combination with contact force sensing catheters and 3-dimensional electroanatomical mapping systems. Energy output and the number of applications were left to the operator’s discretion. RESULTS: Eleven (55%) procedures were conducted under general anesthesia, 6 (30%) under deep sedation, and 3 (15%) under light sedation. Muscular contraction was observed in one case (5%). Median procedural and fluoroscopy times were 95.5 and 6.55 minutes, respectively. The median number of PFA applications was 8 with a median contact force of 10 g . A statistically significant (76%) reduction was observed in mean peak-to-peak bipolar electrogram voltage before and after ablation (0.707 versus 0.098 mV; P =0.008). Ventricular irritative firing was observed in 11 (55%) patients after PFA. The median follow-up was 120 days. Acute procedural success was achieved in 17 of 20 (85% [95% CI, 0.70–1]) patients. Two of the patients with procedural failure had late success with >80% clinical PVC burden suppression during follow-up, and 2 of 17 patients with acute success had late PVC recurrence, which accounts for a total of 17 of 20 (85% [95% CI, 0.70–1]) patients with chronic success. Transient ST-segment depression occurred in 1 patient, and the right bundle branch block was induced in 2 others (permanently only in one case). CONCLUSIONS: PVC ablation using a focal PFA is feasible, effective, and safe, with promising acute and long-term results in several ventricular locations. Irritative firing is frequently observed. Coronary evaluation should be considered when targeting the outflow tract.


  • Open Access

    Impact of gender on the management and prognosis of oesophageal fistula after atrial fibrillation ablation - a subanalysis of the worldwide POTTER-AF study

    by S S Popescu, C H Heeger, V Schmidt, H Puererfellner, J Vogler, D Steven, A Keelani, K H Kuck, J L Merino, R R Tilz

    Background: Oesophageal fistula (OF) is a rare but devastating complication following atrial fibrillation (AF) ablation. The data regarding the impact of gender on the management and prognosis of OF are scarce. Methods: The POTTER-AF study is a worldwide, multi-centre registry conducted under the auspices of the Working Group of Cardiac Electrophysiology of the German Cardiac Society (AGEP, DGK) which evaluated the incidence, management, and outcome of post-procedural OF following catheter ablation of AF. A total of 553 729 patients underwent ablation procedures for AF or atrial tachycardia (AT) in 214 electrophysiological centres from 35 countries between 1996 and 2022. Of them, 138 (0.025%) patients experienced postprocedural OF and data regarding the gender, management and prognosis were available in 117 patients. Herein we conducted a gender- based analysis of the patients exhibiting OF. Purpose: To evaluate the impact of gender on the management and prognosis of OF. Results: Females represented 47% of the study population, which is a notable finding considering that the female population represents only a minority of the patients receiving AF/AT ablation. They were less likely to have atrioesophageal fistula (90.9% vs. 100%; p=0.021). Oesophageal-pericardial fistula occurred solely in females (7.3% vs. 0%; p=0.046). Congestive heart failure was significantly less frequent in the female population (7.4% vs. 26.7%; p=0.012). No other difference was seen between genders regarding the baseline characteristics and comorbidities (Table1). The energy source, ablation technique and utilization of oesophageal temperature probes were similar for males and females. Significantly less women received proton pump inhibitors (PPI) postprocedural (64.8% vs. 84.7%; p=0.017). The median duration until onset of symptoms was 20 days for women and 16.5 days for men (p=0.14), while the median duration until OF diagnosis was 22.5 days and 19.5 days respectively (p=0.217). Significantly more women underwent echocardiography (36.4% vs. 15%; p=0.01) as diagnostic method. More women exhibited stroke (32.7% vs. 14.8%; p=0.040), while there was no significant difference regarding the incidence of septic shock, coma, cardiac arrest, cardiac tamponade, and gastro-intestinal bleeding. Significantly more women than men presented no complications other than OF (9.6% vs. 0%; p=0.026). The females were more likely to undergo endoscopic treatment (35.8% vs. 17.7%; p=0.034), but less likely to undergo direct surgical treatment, without stenting (28.3% vs. 51.6%; p=0.014) (Figure1). The mortality was 63.6% for women and 67.2% for men (p=0.70), with no difference in terms of major and minor sequelae. Conclusion: Approximatively half of the patients exhibiting postprocedural OF are females. Women showed a higher rate of endoscopic treatment and a lower rate of direct surgical treatment. The survival, as well as the incidence of minor and major sequelae were similar between genders.